Baker McKenzie has acted as global counsel to Medtronic plc on the carve-out and spin-off of their diabetes business, MiniMed Group, Inc. MiniMed was listed on Nasdaq on 6 March 2026, and was valued at over USD 5.3 billion at the close of the first day trading. 
 
A diverse range of Baker McKenzie lawyers worked on the global deal including: the central team:  Ben McLaughlin; Tharani Dharmaraj; Phelim O’Doherty; Daniel Relton; Irina Shestakova; Nathan Jones; Patrick Edwards; and Ruby Jenson; the employment team led by Carl Richards; Zelander Gray; and Felipe Graham; the corporate law team: Grace Chia; John Nielsen; JJ Juilfs; Chloe Law; Megan Liew; Ethan McAuliffe; Fin Miller; Amer Nasr; Tara Taylor; Jacob Turner; Frederick Vint and Andrew Tyau; the antitrust team led by Georgina Foster; the intellectual property team led by Natalie Ellerby, Adam Aft; Keo McKenzie; and Mark Gardiner; and the tax team Led by Miles Hurst and Ethan Kroll.  

Medtronic is the leading global healthcare technology company, with a team of more than 95,000 people across more than 150 countries. Medtronic’s technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more.

MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. MiniMed’s integrated ecosystem, including its insulin delivery systems, continuous glucose monitors, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service.

For more information, please see the press release.